drugset / Trial / NCT07225842

The Bridging Antiplatelet Therapy With Cangrelor 2 Study

NCT07225842

Phase 4 Recruiting 50 enrolled University of Florida
NaSingle-groupOpen-labelTreatment

Summary

The primary aim of this study is to determine rates of patients with optimal platelet reactivity range, defined as PRU levels between 85 and 208, when using a (PFT)-guided titration of cangrelor infusion rate (cangrelor titration) compared to 0.75 mcg/kg/min (standard-dose infusion) for bridging.

Timeline

Start
2026-02-18
Primary completion
2027-09
Completion
2027-11

Drugs

EvaluationDrugModalityDoseRoute
Subject Cangrelor Small molecule 0.25 ug/kg
Subject Cangrelor Small molecule 0.5 ug/kg
Subject Cangrelor Small molecule 0.75 ug/kg
Subject Cangrelor Small molecule 1 ug/kg
Subject Cangrelor Small molecule 1.5 ug/kg